## What is claimed:

5

10

15

- 1. A drug comprising a degradable gel with a saturated moisture content not exceeding 98 wt. % and a functional material.
- 2. A drug comprising a degradable gel with a saturated moisture content not exceeding 98 wt. % and a functional material, wherein the release rate of the functional material is controlled by controlling the saturated moisture content of the degradable gel.
  - 3. The drug according to claim 1, wherein the functional material is at least one selected from the group of intrauterine administration drugs, intravaginal administration drugs, intratumoral administration drugs of endometriotic cyst, and intrapelvic administration drugs.
  - 4. The drug according to claim 2, wherein the functional material is at least one selected from the group of intrauterine administration drugs, intravaginal administration drugs, intratumoral administration drugs of endometriotic cyst, and intrapelvic administration drugs.
  - 5. The drug according to claim 1, wherein the functional material is danazol.
  - 6. The drug according to claim 2, wherein the functional material is danazol.
  - 7. The drug according to claim 1, wherein the degradable gel is a polysaccharide gel.
- 20 8. The drug according to claim 2, wherein the degradable gel is a polysaccharide gel.
  - 9. The drug according to claim 7, wherein the polysaccharide gel is an anionic polysaccharide gel.
- 10. The drug according to claim 8, wherein the polysaccharide gel is an anionic25 polysaccharide gel.

- 11. The drug according to claim 1, wherein the degradable gel is a gel obtained through crosslinking reaction using a crosslinking agent.
- 12. The drug according to claim 2, wherein the degradable gel is a gel obtained through crosslinking reaction using a crosslinking agent.
- 5 13. The drug according to claim 11, wherein the crosslinking agent is an epoxy compound having not less than two epoxy groups per molecule.
  - 14. The drug according to claim 12, wherein the crosslinking agent is an epoxy compound having not less than two epoxy groups per molecule.
- 15. The drug according to claim 13, wherein the epoxy compound is ethylene glycoldiglycidyl ether.
  - 16. The drug according to claim 14, wherein the epoxy compound is ethylene glycol diglycidyl ether.
  - 17. The drug according to claim 1, wherein the drug further comprises a surfactant.
  - 18. The drug according to claim 2, wherein the drug further comprises a surfactant.
- 15 19. The drug according to claim 17, wherein the surfactant is a nonionic surfactant.
  - 20. The drug according to claim 18, wherein the surfactant is a nonionic surfactant.
  - 21. In a drug comprising a degradable gel and a functional material, a method for controlled release of a functional material characterized in that the rate of release is controlled by varying the saturated moisture content of the degradable gel.
- 20 22. A preparation process for a drug comprising the steps of:

25

(First step) mixing a functional material and surfactant so as to obtain a surfactant suspension comprising the functional material;

(Second step) dissolving the components of a degradable gel in such proportion to yield a 20 to 80 wt. % aqueous solvent so as to prepare the raw materials solution of a degradable gel; and

(Third step) mixing the surfactant suspension comprising the functional material and the raw materials solution of a degradable gel, and adding a crosslinking agent so as to crosslink the raw materials of a degradable gel.